Market Challenges – Increasing Product Warnings in Sterile Compounding

The major factors that hinder the growth of the U.S. compounding pharmacies market include increasing product warnings in sterile compounding. This has led to a decrease in the sales of compounded injectable drugs, which is also expected to hinder the market growth. For instance, the U.S. Food Drug Administration expanded an original warning on using Becton-Dickinson (BD) general use syringes of sizes 1mL, 3mL, 5mL, 10mL, 20mL, and 30mL. The agency noted that interaction with the rubber stopper in some lots of these syringes may adversely impact drug potency if filled in syringes and not used immediately.

Market Opportunities – Growing Adoption of Compounded Biologics

The growing adoption of compounded biologics presents a significant opportunity for the U.S. compounding pharmacies market. As biologic drugs become more prevalent in treating complex medical conditions like cancer and chronic diseases, the demand for customized medication alternatives is growing. Compounding pharmacies allow for specialized biologics to be created to better suit individual patient needs. This is important as not all U.S. Food and Drug Administration approved drugs work uniformly across different genetic profiles and clinical factors in each person. As biologics continue to revolutionize the treatment of serious diseases, compounded versions provide an important avenue for optimizing patient care through personalization. This emerging opportunity is well-positioned to support significant expansion of the U.S. compounding pharmacies market in the coming years as the chronic illness burden escalates across communities. Catering to this specialized niche with alternatives for hard-to-treat populations can prove integral to the long term growth trajectory of compounding pharmacies market.